PCOS (also called PMOS, polycystic/polyendocrine metabolic ovarian syndrome) is the most common hormonal disorder affecting women of reproductive age. It causes anovulation. And anovulation is why most women with PCOS cannot conceive.
The central question this guide answers is not what PCOS is. It is what to do about it when pregnancy is the goal. The answer depends on understanding one distinction: treatments that restore ovulation by correcting the underlying metabolic and endocrine disorder, and treatments that bypass the disorder entirely.
Six approaches exist. They differ in mechanism, fertility impact, and what they leave behind. This guide covers all six, in the order a restorative approach would consider them. For a full overview of the condition itself, see the PCOS condition guide. For context on the restorative versus bypass comparison, see NaProTechnology versus IVF and IVF alternatives. Both partners are evaluated from the first appointment. Male factor is the sole or primary cause of infertility in approximately 20% of couples. A restorative workup for PCOS-associated infertility includes a semen analysis.
PCOS treatment options at a glance
Six approaches, ordered as a restorative plan would consider them. They differ in whether they correct the underlying disorder or bypass it. Each evidence cell links to the source.
| Approach | What it does | Fertility impact | Evidence |
|---|---|---|---|
| Lifestyle and metabolic correction (weight optimization, inositol, metformin) | Corrects the core PCOS metabolic disturbance: lowers insulin resistance and hyperandrogenism, the drivers of anovulation. Myo-inositol improves ovarian function and metabolic parameters. Metformin restores menstrual cyclicity and raises ovulatory rates. Neither is a band-aid. Both address why the ovary is not ovulating. | Improves baseline ovulation and spontaneous conception odds. Can be sufficient alone in insulin-driven or milder cases. Potentiates response to ovulation induction when used as a foundation layer. Effect is slower than pharmacologic ovulation induction but genuine. | Regidor 2016: myo-inositol improves ovarian function and metabolic parameters in anovulatory PCOS. Vandermolen 2001 (Vandermolen et al., 2001): metformin raises ovulatory and pregnancy rates in clomiphene-resistant PCOS. Glueck 2002 (PMID 11872206): metformin continued through pregnancy reduces gestational diabetes risk. |
| Letrozole (first-line) or clomiphene: ovulation induction | Pharmacologic restoration of ovulation for that cycle. Letrozole is an aromatase inhibitor and the current first-line agent for anovulatory PCOS. Clomiphene is the established alternative. In RRM practice, paired with cycle charting to confirm ovulatory response and optimize timing. | High and direct for anovulatory PCOS with patent tubes and adequate semen parameters. Letrozole produced higher live-birth rates than clomiphene in a 750-woman multicenter randomized controlled trial, with a numerically lower twin rate that did not reach statistical significance, establishing it as the preferred oral agent. | Legro RS et al., N Engl J Med 2014 (PMID 25006718): letrozole vs clomiphene RCT, multicenter, n=750. Letrozole superior on live birth and ovulation with a numerically lower twin rate that did not reach statistical significance. Legro & Zhang 2014: related correspondence in library. |
| Ovarian wedge resection (microsurgical, restorative) | Removes a wedge of androgen-producing ovarian stroma to normalize the hormonal environment and restore ovulation. Corrects the ovary's endocrine output directly. Performed microsurgically with adhesion-prevention technique to minimize post-operative scarring. Genuinely condition-modifying at the ovarian level. | Restores menstrual cyclicity in a large share of treated patients. A critical analysis of 90 cases documented 91% ovulation restoration and a cumulative conception probability of 73% by life-table analysis. Most effective when ovulation is fully restored and no concurrent tubal disease is present. | Adashi 1981: 91% ovulation, 73% cumulative conception (life-table), adhesion caution noted. Szilagyi 1990: measurable drops in androstenedione and DHEA-S after resection. Dahlgren 1992: spontaneous restitution of cyclic regularity over time. |
| Laparoscopic ovarian drilling (destructive) | Electrocautery or laser puncture of multiple points on the ovarian surface to reduce androgen-producing tissue and trigger ovulation. A destructive procedure: it injures rather than reconstructs ovarian tissue. Distinguished from restorative wedge resection by the tissue-destructive mechanism and documented reserve and adhesion risks. | Live-birth rates that may be slightly lower than medical ovulation induction, but with fewer multiple pregnancies and no OHSS risk, in clomiphene-resistant PCOS. A second-line surgical option with known downsides: diminished ovarian reserve and periadnexal adhesion formation are documented consequences. | Bordewijk et al., 2020 (PMID 32048270): LBR may be slightly lower than medical ovulation induction; fewer multiples; no OHSS. |
| IVF (bypass; elevated OHSS risk in PCOS) | Controlled ovarian hyperstimulation, egg retrieval, fertilization outside the body, and embryo transfer. Bypasses the anovulatory disorder without correcting it. The underlying PCOS metabolic and endocrine disturbance remains untreated after IVF. | Effective per cycle but carries PCOS-specific hazards: high antral follicle counts markedly elevate ovarian hyperstimulation syndrome risk. IVF also carries elevated obstetric risk: Almasi-Hashiani and colleagues found a 1.71-fold higher preeclampsia risk with ART versus natural conception. RRM achieved comparable live-birth rates to a single IVF cycle with fewer multiples and fewer preterm births in the first head-to-head comparison. | Almasi-Hashiani 2019: RR 1.71 preeclampsia with ART. PMID 8557121: PCOS and OHSS risk in IVF. Boyle 2025: RRM vs IVF head-to-head, 41% crude LBR, fewer multiples and preterm births. |
| Restorative integrating approach (the RRM frame) | The organizing principle: treat PCOS as a chronic metabolic-endocrine disorder and restore healthy ovulation through layered, individualized correction. Cycle charting confirms the ovulatory response at each stage. The goal is a patient who conceives because her cycle has been restored, not because the disorder was bypassed. | NaProTechnology cohort evidence shows a 62.1% adjusted cumulative take-home-baby rate, with hormonal dysfunction among the predictors of success. Fewer multiples and fewer preterm births than IVF in head-to-head comparison. High repeat-pregnancy success supports it as the default sequencing rather than early escalation to bypass. | Sanchez-Mendez 2025: 62.1% adjusted cumulative take-home baby rate (n=1,310). Boyle 2025: RRM vs IVF, 41% crude LBR, fewer adverse perinatal outcomes. |
Treat the underlying condition first
PCOS is not simply a failure to ovulate. It is a metabolic disorder that produces ovarian consequences. Hyperinsulinemia drives excess androgen production in the ovarian stroma. That androgen excess disrupts follicular development and prevents ovulation. The follicles accumulate rather than rupture. The cycle stalls.
This matters for treatment decisions because it means that medications or procedures targeting only the ovulatory event, without addressing the insulin and androgen environment that is suppressing it, are working against the biology rather than with it.
The restorative frame for PCOS asks: what is driving the anovulation? The answer is nearly always found in the metabolic layer. Insulin resistance and hyperandrogenism are not side features of PCOS. They are the mechanism. Treatments that address them directly restore ovulation more durably than those that trigger it pharmacologically while the underlying disturbance persists.
Cycle charting plays a practical role here. Without documented evidence of ovulatory cycles, including peak-type mucus, a biphasic temperature shift, and a confirmed luteal phase, clinicians cannot distinguish anovulation from oligoovulation, and cannot confirm whether a given intervention is actually restoring ovulatory function or producing incomplete cycles that look like ovulation on a calendar. Treating PCOS without charting is practicing without the most important data available. For context on the fertility awareness methods used in this setting, see the NaProTechnology versus IVF guide.
Lifestyle and metabolic correction
Metabolic correction is the foundation beneath every other PCOS treatment, not an optional add-on. If hyperinsulinemia is driving ovarian androgen excess, then lowering insulin resistance is not a lifestyle recommendation. It is mechanism-directed treatment.
Weight reduction in those with excess adiposity lowers circulating insulin, which directly reduces androgen production and often restores spontaneous ovulatory cycles. The effect is not always sufficient on its own, but it raises the response to every ovulation-induction intervention that follows.
Two insulin-sensitizing drug classes are used in this setting. Myo-inositol, a naturally occurring compound, improves ovarian function and metabolic parameters in anovulatory PCOS. A 2016 review documented improvements in cycle regularity, hormonal profiles, and metabolic markers. (Regidor 2016) Metformin, a biguanide, restores menstrual cyclicity and raises ovulatory and pregnancy rates, with particular benefit in clomiphene-resistant patients. Vandermolen and colleagues demonstrated increased ovulatory rates when metformin preceded clomiphene in resistant cases. (Vandermolen et al., 2001) When continued into pregnancy, metformin appears to reduce gestational diabetes risk, an important consideration given PCOS-related metabolic vulnerability. (Glueck et al., 2002)
Myo-inositol is generally favored for tolerability. Metformin is preferred where insulin resistance and glucose dysregulation predominate. In many cases, both are used together. The point is not which agent but that the metabolic substrate must be addressed before, and alongside, pharmacologic ovulation induction. Neither agent eliminates the need to confirm ovulation through cycle charting.
Ovulation induction
When metabolic correction alone does not restore spontaneous ovulation, pharmacologic ovulation induction is the next step. The goal is still a restored ovulatory cycle, confirmed by charting, not just a triggered event without documented follicular development and luteal adequacy.
Letrozole is the current first-line agent. It is an aromatase inhibitor: it temporarily lowers estrogen, prompting the pituitary to release FSH and drive follicular development. A pivotal multicenter randomized controlled trial enrolled 750 women with PCOS and found that letrozole produced higher ovulation rates, higher pregnancy rates, and higher live-birth rates than clomiphene, with a numerically lower twin rate that did not reach statistical significance. (Legro et al., 2014) That trial displaced clomiphene from first-line status, and letrozole is now the preferred oral agent for anovulatory PCOS across multiple guidelines.
Clomiphene, a selective estrogen-receptor modulator, remains a well-established alternative. It has a longer track record and is more widely available. Where letrozole is unavailable or declined, clomiphene is appropriate. When clomiphene is used, metformin substantially raises the ovulatory and pregnancy rate in resistant patients, as Vandermolen and colleagues demonstrated. (Vandermolen et al., 2001)
Ovulation induction in the restorative setting is cycle-monitored. Charting confirms the ovulatory response and identifies any luteal phase deficiency that the induction did not fully correct. A triggered ovulation without an adequate luteal phase is an incomplete restoration. This is where a clinician experienced in restorative protocols differs from a prescribe-and-wait approach: the monitoring continues past ovulation to confirm the full cycle.
Gonadotropin injections represent a more intensive ovulation induction tier, typically reserved for patients who do not respond to oral agents. They require close monitoring given the higher multiple-pregnancy risk.
Ovarian wedge resection: the restorative surgical option
Ovarian wedge resection removes a wedge of androgen-producing ovarian stroma. It does not bypass anovulation. It corrects the ovary's endocrine output directly by reducing the tissue that is generating excess androgens.
The androgenic drop after resection is measurable. Szilagyi and colleagues documented significant reductions in circulating androstenedione and DHEA-S following the procedure. (Szilagyi 1990) With the hormonal milieu corrected, ovulatory cycles resume in a large share of patients. Dahlgren and colleagues followed women who had undergone wedge resection decades earlier and documented spontaneous restitution of cyclic regularity over time, a natural-history observation. (Dahlgren 1992)
The fertility outcomes after wedge resection are substantial. Adashi and colleagues critically analyzed 90 cases and found 91% ovulation restoration, with a cumulative conception probability of approximately 73% by life-table analysis. (Adashi 1981) Those figures reflect the procedure's ceiling when ovulation is fully restored in patients without concurrent tubal disease. The analysis also noted that adhesion formation and persistent oligoovulation were the main factors that limited conception in those who did not achieve pregnancy after surgery, which is why surgical technique and post-operative monitoring matter.
The historical wedge resection was an open macrosurgical procedure associated with high adhesion rates. Modern microsurgical technique, performed via minilaparotomy or laparoscopy with adhesion-prevention measures, substantially reduces that risk. The procedure is more technically demanding than drilling, and the surgeon's experience with microsurgical technique is a meaningful variable in the outcome.
Wedge resection is appropriately considered when oral ovulation-induction agents have failed or are not tolerated, when the patient prefers a restorative surgical correction, or when ongoing charting reveals persistent anovulation despite metabolic correction and pharmacologic support. For further context on fertility-preserving surgical technique, see fertility-preserving surgery.
Does IVF treat PCOS?
IVF does not treat PCOS. It bypasses the anovulatory disorder by retrieving eggs directly, fertilizing them outside the body, and transferring embryos into the uterus. The underlying metabolic and endocrine disturbance remains entirely in place after IVF. So does the anovulation. The woman who conceives via IVF with untreated PCOS still has PCOS.
PCOS also creates specific IVF hazards. High antral follicle counts, the same feature that produces multiple small follicles and prevents natural ovulation, make the ovaries hyper-responsive to gonadotropin stimulation. Ovarian hyperstimulation syndrome (OHSS) is markedly more likely in PCOS than in other IVF populations. The physiological state that drives anovulation is the same state that raises OHSS risk in stimulation cycles. (PMID 8557121)
The obstetric risk profile of IVF pregnancies also warrants honest disclosure. Almasi-Hashiani and colleagues analyzed 48 studies and found a 1.71-fold higher risk of preeclampsia with assisted reproductive technology compared to natural conception. (Almasi-Hashiani 2019) The first published head-to-head comparison of RRM outcomes versus IVF found that the restorative approach matched a single IVF cycle on live-birth rates while producing fewer multiples, fewer preterm births, and fewer low-birth-weight babies. (Boyle 2025)
The narrative that PCOS requires IVF rests on the premise that ovulation cannot be adequately restored and that conception without assisted retrieval is unlikely. The letrozole trial, the wedge resection data, and the NaProTechnology cohort evidence challenge that premise directly. Restoration-first is not a detour before IVF. It is a different answer to a different question.
How to choose your path
The treatment decision for PCOS-related infertility follows a logic: address the metabolic driver first, restore ovulation by the least invasive means necessary, and escalate only when a lower-tier approach has genuinely failed. Bypass is the last step, not the default.
A few organizing considerations:
- Metabolic correction belongs in every plan, regardless of which other interventions are chosen. Insulin sensitization improves every downstream option. Starting with letrozole alone while hyperinsulinemia and anovulation persist is working against the underlying condition.
- Letrozole is the preferred oral ovulation-induction agent for most anovulatory PCOS patients pursuing fertility. It outperforms clomiphene on live-birth rates in the pivotal trial. In clomiphene-resistant patients who have not yet tried letrozole, switching to letrozole before surgical escalation is the correct sequence.
- When oral agents fail or are not tolerated, ovarian wedge resection is the restorative surgical option. It corrects the ovarian endocrine output rather than damaging tissue. A skilled microsurgeon with adhesion-prevention technique is essential to the outcome. Ovarian drilling is destructive by mechanism: it is a lesser surgical option with documented ovarian-reserve and adhesion consequences, considered only when restorative surgery is not available or when another laparoscopic indication is already present.
- Cycle charting is not optional in a restorative approach. Without documented ovulatory cycles, clinicians cannot confirm whether any intervention is actually working at the level of ovulation and luteal adequacy. If current care does not include charting, that is a gap worth addressing.
- Both partners should be evaluated before surgical escalation. Male factor is the sole or primary cause of infertility in approximately 20% of couples. A semen analysis should precede any discussion of ovarian surgery.
- IVF is a last-resort option for PCOS-related infertility, not a first step. It carries PCOS-specific OHSS risk, leaves the underlying disorder untreated, and carries an elevated obstetric risk profile. The question to ask before considering IVF: has the underlying anovulation been treated, or has it been bypassed?
To find an RRM clinician experienced in restorative evaluation and treatment for PCOS, visit rrmacademy.org/providers/. For a full comparison of the restorative and bypass approaches, see NaProTechnology versus IVF and IVF alternatives. For the PCOS condition overview, see PCOS condition guide.
Continue exploring
References
- Regidor PA, Schindler AE. Myo-inositol in the treatment of infertile women with polycystic ovary syndrome: an observational study. International Journal of Endocrinology. 2016. PMID 27642297. View in RRM Library
- Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine. 2014;371(2):119-129. doi:10.1056/NEJMoa1313517. PMID 25006718.
- Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene alone. Fertility and Sterility. 2001;75(2):310-315. PMID 11172832. View in RRM Library
- Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertility and Sterility. 2002;77(3):520-525. PMID 11872206. View in RRM Library
- Szilagyi A, Rossmanith W, Csermely T, Csaba I. Changes in circulating hormone levels after ovarian wedge resection. Archives of Gynecology and Obstetrics. 1990;248(1):31-35. PMID 2124095. View in RRM Library
- Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up. Fertility and Sterility. 1992;57(3):505-513. PMID 1740195. View in RRM Library
- Adashi EY, Rock JA, Guzick D, et al. Fertility following bilateral ovarian wedge resection: a critical analysis of 90 consecutive cases. Fertility and Sterility. 1981;36(3):320-325. PMID 7286253. View in RRM Library
- Bordewijk EM, Ng KYB, Rakic L, et al. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2020;(2):CD001122. doi:10.1002/14651858.CD001122.pub5. PMID 32048270. View in RRM Library
- Buyalos RP, Lee CT. Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. Fertility and Sterility. 1996;65(1):1-10. PMID 8557121. View in RRM Library
- Almasi-Hashiani A, Omani-Samani R, Mohammadi M, et al. Assisted reproductive technology and the risk of preeclampsia: an updated systematic review and meta-analysis. BMC Pregnancy and Childbirth. 2019;19(1):149. doi:10.1186/s12884-019-2291-x. PMID 31046710. View in RRM Library
- Sanchez-Mendez JI, Lombarte M, Abengozar-Muela R, et al. Natural procreative technology (NaProTechnology) for infertility: take-home baby rate and clinical outcomes in a 5-year single-center cohort of 1,310 couples. Frontiers in Reproductive Health. 2025;7:1696679. doi:10.3389/frph.2025.1696679. PMID 41323405. View in RRM Library
- Boyle P, Toth A, Minjeur M, Turczynski C. Restorative reproductive medicine (RRM) outcomes compared to in-vitro fertilization (IVF) for the treatment of infertility: a retrospective evaluation of a 2019 clinic cohort. Journal of Restorative Reproductive Medicine. 2025;1. doi:10.63264/gejytw70. View in RRM Library
Frequently Asked Questions
What is the best PCOS treatment for getting pregnant?
In many cases, the most effective path begins with correcting the metabolic drivers of anovulation, then restoring ovulation with the least invasive intervention necessary. Myo-inositol and metformin address the insulin resistance and hyperandrogenism that suppress ovulation in PCOS. When metabolic correction alone is insufficient, letrozole is the first-line oral agent: a 750-woman randomized controlled trial found it produces higher live-birth rates than clomiphene with a numerically lower twin rate that did not reach statistical significance. (Legro et al., 2014) When oral agents fail, ovarian wedge resection corrects the ovary's hormonal output directly, with cumulative conception probabilities up to 73% in published series. (Adashi 1981) Bypass approaches leave the underlying disorder in place. A restorative clinician can help determine which step is right for your situation. Consult an RRM clinician for guidance specific to your situation.
Does PCOS affect fertility?
PCOS (also called PMOS, polycystic/polyendocrine metabolic ovarian syndrome) is the leading cause of anovulatory infertility. The mechanism is direct: hyperinsulinemia drives excess androgen production in the ovary, which disrupts follicular development and prevents ovulation. Without ovulation, conception cannot occur. The good news is that anovulation in PCOS is among the most treatable causes of infertility. Letrozole restores ovulation and produces live births in a large share of treated patients. Metabolic correction with inositol or metformin further improves the ovulatory environment. For medication-resistant cases, ovarian wedge resection can restore spontaneous cyclicity. A NaProTechnology cohort of 1,310 patients found a 62.1% adjusted cumulative take-home-baby rate, with hormonal dysfunction among the predictors of success. (Sanchez-Mendez 2025) Consult an RRM clinician for guidance specific to your situation.
Is letrozole better than clomiphene for PCOS?
For most anovulatory PCOS patients, the evidence favors letrozole. A multicenter randomized controlled trial enrolled 750 women with PCOS-related anovulatory infertility and found that letrozole produced higher ovulation rates, higher pregnancy rates, and higher live-birth rates than clomiphene, with a numerically lower twin rate that did not reach statistical significance. (Legro et al., 2014) Letrozole works by temporarily lowering estrogen to prompt FSH release and follicular development. Clomiphene blocks estrogen receptors and can thicken cervical mucus, a drawback letrozole avoids. Clomiphene remains a reasonable alternative where letrozole is unavailable or declined. In clomiphene-resistant patients, metformin substantially raises the ovulatory rate when added before clomiphene. (Vandermolen et al., 2001) In a restorative approach, cycle charting confirms the ovulatory response and identifies any luteal adequacy issues the medication did not fully correct. Consult an RRM clinician for guidance specific to your situation.
What is ovarian wedge resection and is it still used for PCOS?
Ovarian wedge resection removes a wedge of androgen-producing ovarian stroma to normalize the hormonal environment and restore ovulation. It directly corrects the ovary's endocrine output rather than simply triggering ovulation pharmacologically. The procedure fell out of favor due to adhesion risks with older open surgical technique, but modern microsurgical approaches via minilaparotomy or laparoscopy with adhesion prevention have substantially changed that risk profile. Published data document 91% ovulation restoration and a cumulative conception probability of approximately 73% in patients without concurrent tubal disease. (Adashi 1981) Long-term follow-up shows spontaneous restitution of cyclic regularity over time in many patients. (Dahlgren 1992) It remains a valid restorative surgical option for medication-resistant PCOS when performed by a skilled microsurgeon. Consult an RRM clinician for guidance specific to your situation.
What is the difference between ovarian drilling and ovarian wedge resection?
The fundamental difference is the mechanism. Wedge resection removes a section of androgen-producing ovarian stroma, correcting the ovary's endocrine output. It is restorative by design. Drilling uses electrocautery or laser to puncture multiple points on the ovarian surface, destroying tissue to reduce androgen production. It is destructive by mechanism. Both can reduce androgens and restore ovulation in medication-resistant PCOS. A 2020 Cochrane review found drilling produced live-birth rates that may be slightly lower than medical ovulation induction, with fewer multiple pregnancies and no OHSS risk. (Bordewijk et al., 2020) The documented concern with drilling is ovarian-reserve reduction and periadnexal adhesion formation. Where a skilled microsurgeon is available, wedge resection is the restorative surgical option. Drilling is the lesser alternative when restorative surgery is not feasible. Consult an RRM clinician for guidance specific to your situation.
Does IVF treat PCOS?
IVF does not treat PCOS. It bypasses the anovulatory disorder by retrieving eggs directly and transferring embryos, leaving the underlying metabolic and endocrine disturbance entirely in place. PCOS also creates a specific IVF hazard: high antral follicle counts make ovarian hyperstimulation syndrome markedly more likely during stimulation cycles. The same physiology that prevents natural ovulation is the physiology that raises OHSS risk. Beyond that, IVF pregnancies carry elevated obstetric risks: Almasi-Hashiani and colleagues found a 1.71-fold higher risk of preeclampsia with assisted reproductive technology. (Almasi-Hashiani 2019) A restorative approach that restores ovulation addresses the condition. IVF routes around it. Consult an RRM clinician for guidance specific to your situation.
Can PCOS anovulation be treated without IVF?
In many cases, yes. Anovulatory PCOS is one of the most treatment-responsive causes of infertility. Metabolic correction with myo-inositol and metformin restores spontaneous cycles in a meaningful share of patients. Letrozole, the first-line oral agent, produced higher live-birth rates than clomiphene in a 750-woman trial. (Legro et al., 2014) For medication-resistant cases, ovarian wedge resection corrects the ovary's androgen output and restores cyclicity durably in many patients. A NaProTechnology cohort study reported a 62.1% adjusted take-home-baby rate at 36+ months across a population that included PCOS patients, with fewer multiples and fewer preterm births than IVF comparison data. (Sanchez-Mendez 2025) IVF is one option; restoring ovulation is a different answer to a different question. Consult an RRM clinician for guidance specific to your situation.
This content is for educational and reference purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified clinician about your specific situation.